DeWeerd Alexander J, Sun Elizabeth, Iams Wade T
Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Vanderbilt University School of Medicine, Nashville, Tennessee.
JTO Clin Res Rep. 2025 Feb 12;6(7):100805. doi: 10.1016/j.jtocrr.2025.100805. eCollection 2025 Jul.
Although drug-induced interstitial lung disease has been reported with cancer-directed antibody-drug conjugates and EGFR tyrosine kinase inhibitors, it remains a rare event in patients treated with amivantamab. In this report, we present two cases of suspected amivantamab-related drug-induced interstitial lung disease in patients with canonical EGFR mutant NSCLC after progression on osimertinib.
尽管已有使用癌症导向抗体药物偶联物和表皮生长因子受体（EGFR）酪氨酸激酶抑制剂导致药物性间质性肺病的报道，但在接受阿美替尼治疗的患者中，这种情况仍然罕见。在本报告中，我们介绍了两例在奥希替尼治疗进展后，患有经典EGFR突变非小细胞肺癌（NSCLC）的患者疑似阿美替尼相关药物性间质性肺病的病例。
